-2.7%
CEG vs MRNA
+511.3%
-514.0%
-41.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.9% | -2.2% | +7.1% | +4.9% |
| 7D | +8.0% | +5.5% | +2.5% | +7.9% |
| 30D | +12.9% | +158.7% | -145.8% | +8.9% |
| 3M | +13.2% | +182.1% | -169.0% | +8.3% |
| 6M | -7.0% | +151.8% | -158.8% | -11.1% |
| YTD | -15.0% | +393.6% | -408.6% | -20.0% |
| 1Y | -2.7% | +499.5% | -502.2% | -9.3% |
| All | -2.7% | +511.3% | -514.0% | -9.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling